Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2016-001502-42-Outside-EU/EEA
EUCTR2016-001502-42-Outside-EU/EEA
Active, not recruiting
Phase 1

Effect of Early Growth Hormone Treatment on Long-term Growth and Skeletal Maturation in Girls With Turner Syndrome

Eli Lilly and Company Limited0 sites88 target enrollmentJune 23, 2016
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsTurner SyndromeMedDRA version: 19.0Level: LLTClassification code 10063020Term: Parsonage-Turner syndromeSystem Organ Class: 100000004852Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
DrugsHumatrope / Umatrope

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Turner Syndrome
Sponsor
Eli Lilly and Company Limited
Enrollment
88
Status
Active, not recruiting
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 23, 2016
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Previously randomized in study B9R\-US\-GDFG; karyotype\-proven Turner syndrome
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range: 88
  • •F.1\.2 Adults (18\-64 years) no
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) no
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •Immediate family members of study site personnel directly affiliated with the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 4
Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner SyndromeTurner Syndrome
NCT00266656Eli Lilly and Company69
Completed
Phase 3
Influence of adding growth hormone in frozen embryo transfer cycle outcome
IRCT20091018002604N5Vice chancellor for research,Shahid Sadoughi University of Medical Science,Yazd,Iran100
Completed
Phase 2
Influence of exogenous growth hormone administration on circulating levels of Klotho in healthy and chronic kidney disease subjects
NL-OMON40366Vrije Universiteit Medisch Centrum20
Active, not recruiting
Not Applicable
Influence of growth hormone administered subcutaneously on circulating Klotho levels in healthy subjects and subjects with renal failure.Cardiovascular disease in chronic kidney diseaseTherapeutic area: Body processes [G] - Metabolic Phenomena [G03]
EUCTR2013-003354-24-NLVrij Universiteit Medical Center
Completed
Not Applicable
Influence of exogenous growth hormone administration on circulating levels of Klotho in paediatric patients with isolated growth hormone deficiency.Klotho levels in isolated growth hormone deficiency10021112
NL-OMON44245Vrije Universiteit Medisch Centrum20